Celldex Therapeutics, Inc.
NASDAQ:CLDXBiotechnology
+$0.16 today
- Market cap
- $2.16B
- Beta
- 0.93
- P/E (TTM)
- -7.8
- EPS (TTM)
- -$4.26
Volume 0.68M
Average 0.94M
CLDX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Celldex Therapeutics, Inc.NASDAQ: CLDX
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development grows, but more slowly than its trailing trend
Q3 FY2026 research & development of $67.41M rose 7.1% year over year, behind the +31.2% change in trailing-twelve-month research & development. Sequentially, it fell 0.2% from the prior quarter. Over 3 fiscal years it compounded at +43.9% a year.
Context
- Research & development amounted to 16340.0% of revenue in FY2025, up 14010.2 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +7.1% toward the trailing-twelve-month pace of +31.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 245.1M USD
- Year-over-year change
- +49.9%
- 4-year CAGR
- +44.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 245.1M | +49.9% |
| FY2024 | 2024-12-31 | 163.55M | +38.6% |
| FY2023 | 2023-12-31 | 118.01M | +43.5% |
| FY2022 | 2022-12-31 | 82.26M | +44.8% |
| FY2021 | 2021-12-31 | 56.81M | — |
Research & Development vs competitors
How CLDX compares with its peers on the latest reported figures
- CLDX's LTM Sep 2026 research & development of $283.32M is the 3rd highest of the 10 companies compared; the peer median is $135.36M.
- Its year-over-year change of +31.2% is the 2nd highest of 9, against a peer median of +6.4%.
- Research & development amounts to 252960.7% of revenue for CLDX, versus a peer median of 86.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $497M | +2.5% | +22.0% | 424.8% | |
| LTM Aug 2026 | $331.95M | +10.2% | +18.6% | 47.3% | |
| LTM Sep 2026 | $283.32M | +31.2% | +43.9% | 252960.7% | |
| LTM Jun 2026 | $255.77M | +11.4% | +6.3% | 243.6% | |
| LTM Sep 2026 | $236.54M | +35.6% | +95.7% | — | |
| LTM Mar 2026 | $135.36M | -19.9% | -12.2% | 86.2% | |
| LTM Mar 2026 | $56.29M | +22.7% | +23.1% | — | |
| LTM Mar 2026 | $38.53M | -58.1% | — | 31.1% | |
| LTM Jun 2024 | $30.07M | — | -35.3% | 3686.7% | |
| LTM Mar 2026 | $23.92M | -1.0% | -9.4% | 32.9% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding CLDX) | $135.36M | +6.4% | +12.5% | 86.2% | |
Competitors are the stored peer set for CLDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.65M | 2.36M | 6.88M | 7.02M | 1.5M |
| Cost of Revenue | 53.31M | 82.26M | 118.01M | 163.55M | 0 |
| Gross Profit | (48.66M) | (79.9M) | (111.13M) | (156.53M) | 1.5M |
| Gross Margin | -1046.2% | -3389.9% | -1614.5% | -2229.8% | 100.0% |
| Research & Development | 56.81M | 82.26M | 118.01M | 163.55M | 245.1M |
| Selling, General & Admin | 20.49M | 27.2M | 30.91M | 38.55M | 43.8M |
| Operating Expenses | 22.58M | 35.33M | 43.41M | 38.55M | 288.9M |
| Depreciation & Amortization | 3.07M | 2.9M | 3.01M | 3.18M | 3.38M |
| EBITDA | (66.08M) | (104.2M) | (139.03M) | (154.69M) | (255.42M) |
| EBITDA Margin | -1420.8% | -4420.9% | -2020.0% | -2203.5% | -17028.0% |
| Operating Income | (71.24M) | (115.23M) | (154.54M) | (195.08M) | (287.4M) |
| Operating Margin | -1531.8% | -4889.0% | -2245.3% | -2778.9% | -19160.0% |
| Interest Income | 505K | 2.91M | 13.11M | 37.22M | 28.61M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 505K | 2.91M | 13.11M | 37.22M | 28.6M |
| Income Before Tax | (70.74M) | (112.33M) | (141.43M) | (157.86M) | (258.8M) |
| Pre-Tax Margin | -1520.9% | -4765.6% | -2054.8% | -2248.8% | -17253.3% |
| Income Tax Expense | (227K) | 0 | 0 | 0 | 0 |
| Net Income | (70.51M) | (112.33M) | (141.43M) | (157.86M) | (258.8M) |
| Net Margin | -1516.0% | -4765.6% | -2054.8% | -2248.8% | -17253.3% |
| EPS (Basic) | (1.64) | (2.40) | (2.92) | (2.45) | (3.90) |
| EPS (Diluted) | (1.64) | (2.40) | (2.92) | (2.45) | (3.90) |
| Weighted Avg Shares | 42.87M | 46.89M | 48.45M | 64.4M | 66.5M |
| Weighted Avg Shares (Diluted) | 42.87M | 46.89M | 48.45M | 64.4M | 66.5M |
Celldex Therapeutics, Inc.
NASDAQ:CLDX
Intrinsic Alpha fair value
Locked
Current Price
$27.55
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.